Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
IPO Year: 2018
Exchange: NASDAQ
Website: gamida-cell.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/16/2021 | $14.00 → $12.00 | Buy | Needham |
| 11/16/2021 | $17.00 → $15.00 | Outperform | Oppenheimer |
| 11/1/2021 | $11.00 | Buy | Alliance Global Partners |
4 - Gamida Cell Ltd. (0001600847) (Issuer)
4 - Gamida Cell Ltd. (0001600847) (Issuer)
4 - Gamida Cell Ltd. (0001600847) (Issuer)
4 - Gamida Cell Ltd. (0001600847) (Issuer)
4 - Gamida Cell Ltd. (0001600847) (Issuer)
4 - Gamida Cell Ltd. (0001600847) (Issuer)
4 - Gamida Cell Ltd. (0001600847) (Issuer)
4 - Gamida Cell Ltd. (0001600847) (Issuer)
4 - Gamida Cell Ltd. (0001600847) (Issuer)
4/A - Gamida Cell Ltd. (0001600847) (Issuer)
For Immediate Release: April 17, 2023 Today, the U.S. Food and Drug Administration approved Omisirge (omidubicel-onlv), a substantially modified allogeneic (donor) cord blood-based cell therapy to quicken the recovery of neutrophils (a subset of white blood cells) in the body and reduce the risk of infection. The product is intended for use in adults and pediatric patients 12 years and older with blood cancers p
Needham reiterated coverage of Gamida Cell with a rating of Buy and set a new price target of $12.00 from $14.00 previously
Oppenheimer reiterated coverage of Gamida Cell with a rating of Outperform and set a new price target of $15.00 from $17.00 previously
Alliance Global Partners initiated coverage of Gamida Cell with a rating of Buy and set a new price target of $11.00
Needham & Company LLC reiterated coverage of Gamida Cell with a rating of Buy and set a new price target of $14.00 from $17.00 previously
Piper Sandler reiterated coverage of Gamida Cell with a rating of and set a new price target of $23.00 from $25.00 previously
Needham reiterated coverage of Gamida Cell with a rating of Buy and set a new price target of $14.00 from $17.00 previously
HC Wainwright resumed coverage of Gamida Cell with a rating of Buy and set a new price target of $27.00 from $15.00 previously
Oppenheimer resumed coverage of Gamida Cell with a rating of Buy and set a new price target of $17.00